Market news — every asset we track

Assets

ENTA

Enanta Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright

Sep 23Investing.com

Enanta Pharmaceuticals to Participate in September Investor Conferences

WATERTOWN, Mass., September 01, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in two investor conferences in September:

Sep 1Yahoo Finance

ENTA

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates

Aug 10Yahoo Finance

ENTA

Enanta earnings missed by $0.17, revenue fell short of estimates

Aug 10Investing.com

ENTA

Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot

Aug 10Barchart.com

ENTA

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

WATERTOWN, Mass., August 10, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2026.

Aug 10Yahoo Finance

ENTA

Enanta Pharmaceuticals Establishes Flexible At-The-Market Offering

Detailed price information for Enanta Pharmaceutica (ENTA-Q) from The Globe and Mail including charting and trades.

Jul 3The Globe and Mail

ENTA

This is the newest page. Registered accounts read further back.